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Available online xxxxGaucher disease (GD) may worsen during pregnancy, leading to the discussion of continuing treatment during
pregnancy. We examined fetal outcomes of pregnancies reported in the Gaucher Outcome Survey, an interna-
tional GD-speciﬁc registry established in 2010. A total of 453 pregnancies were reported. Most pregnancies
(336/453, 74.2%) were in women who did not receive GD-speciﬁc treatment during pregnancy, while enzyme
replacement therapy (ERT) was received during 117/453 (25.8%) pregnancies. No pregnancies exposed to sub-
strate reduction therapy were reported. The percentage of normal outcomes (live birth delivered at term with
no congenital abnormalities) was similar in untreated and treated pregnancies (92.9% vs. 91.4%). The percentage
of spontaneous abortions in untreated pregnancies was 3.6% (95% CI, 1.9%– 6.2%) compared with 6.9% (95% CI,
3.0%–13.1%) in treated pregnancies (p = 0.1866). In women who received velaglucerase alfa b1 month prior
to conception and/or during pregnancy, 34/36 (94.4%) pregnancies had normal outcomes and 2 (5.6%) ended
in spontaneous abortion. Normal outcomes were observed in the 20 pregnancies with velaglucerase alfa expo-
sure starting b1month prior to conception and continuing through all trimesters. These observations, in addition
to information in the literature, suggest that continuation of ERT during pregnancy may be appropriate for GD
patients.
© 2016 Elsevier Inc. All rights reserved.Keywords:
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The lysosomal storage disorder Gaucher disease (GD), is caused by a
deﬁciency of the enzyme β-glucocerebrosidase. Signs and symptoms of
the disease result from accumulation of the enzyme's glycolipide replacement therapy; GD,
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Cells Mol. Diseases (2016), hsubstrate in the cells of the monocyte-macrophage system. Type 1 GD
is the most common form of the disease, predominantly affecting the
hematologic, visceral, and skeletal systems. The acute (type 2) and
chronic (type 3) neuronopathic forms of the disease affect a minority
of GD patients [1]. Pregnancy has been reported to exacerbate disease
manifestations in women with GD and patients may be at higher risk
of experiencing complications such as bleeding during delivery and
postpartum [2,3].
Enzyme replacement therapy (ERT) with recombinant β-
glucocerebrosidase is available for patients with symptomatic type 1
and type 3 GD and is effective for improving hematological and visceral
disease manifestations [4,5]. The ﬁrst ERT for GD, alglucerase, became
available in 1991, and those currently available are imiglucerase,
velaglucerase alfa and taliglucerase alfa.
The use of alglucerase or imiglucerase during pregnancy in symp-
tomatic patients with GD has been associated with a reduced incidencettp://dx.doi.org/10.1016/j.bcmd.2016.10.003
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and postpartum compared with untreated patients [2]. A study of
women with GD who were exposed to velaglucerase alfa during preg-
nancy, some of whom may be included in the analysis presented here,
reported normal outcomes for 21 of 25 pregnancies (the remaining 4
ended in early ﬁrst trimester missed abortions), and postpartum com-
plications in only 1 of 21 pregnancies (placental tear and bleeding,
which resolved without intervention) [6].
Oral substrate reduction therapies (SRTs) with glucosylceramide
synthase inhibitors have also demonstrated efﬁcacy for the treatment
of type 1GD. The two approved SRTs,miglustat and eliglustat, have sim-
ilarmechanisms of action but are structurally different and have distinct
side-effect proﬁles. Eliglustat is the only SRT approved as a ﬁrst-line
therapy for adults with type 1 GD. There are limited data on the use of
SRT in human pregnancy. In animal studies, maternal death has been
observed with miglustat and fetal harm has been shown with both
eliglustat and miglustat [7,8].
Risk summaries and guidance provided in product labeling on the
use of GD-speciﬁc ERTs and SRTs during pregnancy in the United
States and the European Union vary (Table 1).
Recommendations published in 2011 by a panel of GD experts pro-
pose that asymptomatic patients should not be advised to start ERT be-
fore pregnancy, and that the initiation of ERT during pregnancy should
only be considered if there is a clear worsening of several disease pa-
rameters [9]. For symptomatic patients not receiving treatment, starting
ERT before pregnancy may help prevent worsening of disease parame-
ters and GD-related complications during pregnancy. Patients already
on treatment should be encouraged to remain on treatment during
pregnancy at their pre-pregnancy dose, though dose adjustments dur-
ing pregnancy could be considered if disease parameters worsen. The
decision to start or continue treatment during pregnancy is based on a
patient's informed decision, which must be respected.
The overall objective of this study was to assist pregnant women
with GD and their physicians in their consideration of treatment during
pregnancy. We sought to obtain evidence by evaluating the fetal out-
comes of pregnancies in GD patients using real-life data from the
Gaucher Outcome Survey (GOS). GOS is an international observational
GD-speciﬁc registry established in 2010. Patientswith a conﬁrmeddiag-
nosis of GD can be enrolled in GOS regardless of their GD type or treat-
ment status. The registry is designed to document the clinical outcomeTable 1
Key statements regarding pregnancy in the labeling information for GD-speciﬁc treat-
ments in the United States and European Union.a
Treatment
name
United States Prescribing
Information
European Medicines Agency
Summary of Product
Characteristics
Imiglucerase
(Cerezyme®)
“Cerezyme should not be
administered during
pregnancy except when the
indication and need are clear
and the potential beneﬁt is
judged by the physician to
substantially justify the risk”
[18].
“Treatment naïve women
should be advised to consider
commencing therapy prior to
conception in order to attain
optimal health”.
“In women receiving Cerezyme
treatment continuation
throughout pregnancy should
be considered” [14].
Velaglucerase
alfa
(VPRIV®)
“VPRIV should be used during
pregnancy only if clearly
needed” [17].
“Caution should be exercised
when prescribing to pregnant
women” [23].
Miglustat
(Zavesca®)
“Zavesca should be used during
pregnancy only if the potential
beneﬁt justiﬁes the potential
risk to the fetus” [7].
“Miglustat crosses the placenta
and should not be used during
pregnancy” [15].
Eliglustat
(Cerdelga®)
“Cerdelga should be used
during pregnancy only if the
potential beneﬁt justiﬁes the
potential risk to the fetus” [8].
“As a precautionary measure, it
is recommended to avoid the
use of Cerdelga during
pregnancy” [24].
a Refer to referenced prescribing information and summaries of product characteristics
for complete risk summaries and labeling regarding use of these treatments in pregnancy.
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pects of GD, such as key disease features, treatment patterns, and med-
ical history. In collaborationwith GD experts at 34medical centers in 11
countries, GOS has 1094 patients enrolled as of July 2016. Here we re-
port on the pregnancy events in patients enrolled in GOS at the time
of the July 30, 2015 data extract.2. Patients and methods
2.1. Pregnancy data collected
Data on pregnancy events were collected via the GOS electronic case
report form (Supplementary Table 1). The form was completed for
pregnancies of enrolled females and may include pregnancies that oc-
curred before enrollment into GOS.
Data on patients' GBA1 genotype was provided via selection from a
prespeciﬁed list or entered as free text. Free-text entries weremanually
reclassiﬁed into one of eight categories following review by a GOS study
medical monitor.
Information on GD-speciﬁc treatment status and treatment received
during pregnancy was collected. GD-speciﬁc treatments were deﬁned
as the ERTs alglucerase, imiglucerase, velaglucerase alfa, and
taliglucerase alfa, and the SRTs, miglustat and eliglustat. If a patient re-
ceived velaglucerase alfa, additional information on the dose received
and timing of treatment during pregnancy was obtained (the timing
of treatment during pregnancy could only be entered for velaglucerase
alfa as it was not requested for other treatments received during preg-
nancy [Supplementary Table 1]).
Information on fetal outcomes was provided via selection from a
pre-speciﬁed list. Outcomes in the list were: normal, spontaneous abor-
tion, elective abortion, neonatal death, intrauterine stillbirth, stillbirth
during delivery, and congenital abnormality. A normal pregnancy out-
come indicates a delivery at term resulting in a live birth with no con-
genital abnormalities.2.2. Analysis
Pregnancy data were analyzed for the overall cohort and in sub-
groups based on GD-speciﬁc treatment status during pregnancy: 1) pa-
tients who received velaglucerase alfa; 2) patients who received GD-
speciﬁc treatment other than velaglucerase alfa (imiglucerase,
alglucerase or taliglucerase alfa; no pregnancies exposed to SRT were
reported); and 3) patients who did not receive any GD-speciﬁc
treatment.
For comparison of pregnancy outcomes in untreated pregnancies
and those exposed to GD-speciﬁc treatment, the percentage of pregnan-
cies with a normal outcome or ending in spontaneous abortion and 95%
exact conﬁdence interval (CI) for percentages were calculated. A p-
value for the Fisher exact test of no difference in probability of a speciﬁc
pregnancy outcome (normal or spontaneous abortion) was also calcu-
lated, assuming independence between pregnancies occurring in the
same patient. Calculated p-values are results of exploratory analysis
and should be interpreted descriptively; p-values over a prespeciﬁed
signiﬁcance level (5%) cannot be interpreted as evidence of no differ-
ence between groups.2.3. Adverse events
No data on pregnancy-related or GD-related complications during
pregnancy were collected in the pregnancy form. Information on any
adverse events that occurred at any time inwomen in the pregnancy co-
hort were extracted and reviewed by a GOS medical monitor. The start
and stop dates of the events and the end date of pregnancywere used to
determine whether an adverse event occurred during pregnancy.ttp://dx.doi.org/10.1016/j.bcmd.2016.10.003
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3.1. Baseline demographics
Pregnancies were reported for 189 women enrolled in GOS
(Table 2). The women had a median (interquartile range [IQR]) age at
GD symptom onset of 17.3 (8.6–26.9) years and a median (IQR) age at
time of GD diagnosis of 19.4 (9.3–28.4) years. The most common GBA1
genotype in the women with available data was N370S/N370S (93/
162, 57.4%).
3.2. Pregnancy events, overall cohort of treated and untreated patients
A total of 453 pregnancies with delivery or end dates from January
1959 to July 2015were reported (Fig. 1).Most pregnancieswere report-
ed from Israel (368/453, 81.2%; Supplementary Fig. 1). For patients with
GD type provided (188/189, 99.5%), all pregnancies were in patients
with type 1 GD, except for two in one woman with type 3 GD. Both of
the type 3 GD patient's pregnancies occurred in the late 1970s before
ERTwas available. Her ﬁrst pregnancy, at age 19, resulted in a spontane-
ous abortion, while her second pregnancy, at age 21, had a normal
outcome.
Of the 452 outcomes reported for 453 pregnancies, 418 (92.5%) had
normal outcomes (delivery at term resulting in a live birth with no con-
genital abnormalities). The median (IQR) age of patients at delivery for
pregnancieswith normal outcomeswas 29.5 (25.3, 33.1) years (Supple-
mentary Table 2). For the remainder of pregnancies with speciﬁed out-
comes, 20 (4.4%) resulted in spontaneous abortion, 13 (2.9%) in elective
abortion, and 1 (0.2%) in neonatal death (Table 3).
3.3. Pregnancies in patients receiving velaglucerase alfa
There were 36 pregnancies with exposure to velaglucerase alfa b
1 month before conception or at some time during pregnancy, 34
(94.4%) of which had normal outcomes (Table 4). For the pregnancies
with dose information (33 dose entries for 30 pregnancies), velaglucerase
alfa was received at b20 U/kg in 14 entries and ≥20 U/kg in 19 entries.
Two (2/36, 5.6%) pregnancies with exposure to velaglucerase alfa
and ending in spontaneous abortion were reported in one patient. In
both instances, the patient received velaglucerase alfa (15 U/kg every
other week) prior to conception, but not during pregnancy. She subse-
quently had a pregnancy with a normal outcome where she receivedTable 2
Demographics of women with pregnancies reported in GOS (n = 189).
Characteristics Patients (n = 189)
GD type, n (%)a
Type 1 187 (99.5)
Type 3 1 (0.5)
Missing information 1
GBA1 genotype, n (%)a,b
[c.1226A N G] + [c.1226A N G] (N370S/N370S) 93 (57.4)
[c.1226A N G] + [c.1448 T N C] (N370S/L444P) 14 (8.6)
[c.1226A N G] + [c.84dupG] (N370S/84GG) 12 (7.4)
[c.1226A N G] + Other (N370S/other) 31 (19.1)
[c.1226A N G] + Unknown (N370S/unknown) 8 (4.9)
[c.1448 T N C] + Other (L444P/other) 1 (0.6)
Other/other 3 (1.9)
Missing information 27
Age at GD symptom onset, median (IQR) years 17.3 (8.6, 26.9)
Age at GD diagnosis, median (IQR) years 19.4 (9.3, 28.4)
Age at end of pregnancyc, median (IQR) years 29.5 (25.2, 33.0)
GD, Gaucher disease; GOS, Gaucher Outcome Survey; IQR, interquartile range.
a Percentages determined from number of patients with available data.
b GBA1 genotype numbers obtained following reclassiﬁcation that occurred outside the
database entry (manual reclassiﬁcation of free-text entries), which must be considered.
c Age at end of pregnancy for pregnancies with at least a delivery or end year available
(n = 440 pregnancies; patients could have more than one pregnancy reported).
Please cite this article as: H. Lau, et al., Blood Cells Mol. Diseases (2016), hthe same dose of velaglucerase alfa before conception and during her
ﬁrst and second trimesters.
Of the 36 pregnancies with exposure to velaglucerase alfa, there
were 20 during which treatment was received before conception and
in all trimesters (Table 5). All 20 of these pregnancies had normal
outcomes.
3.4. Pregnancies in patients receiving GD-speciﬁc treatment other than
velaglucerase alfa
There were 81 pregnancies with exposure to GD-speciﬁc treatment
other than velaglucerase alfa, namely alglucerase (n= 6), imiglucerase
(n = 63), or taliglucerase alfa (n = 6, treatment not speciﬁed in six;
Table 4).
In pregnancies with exposure to alglucerase, all six had normal out-
comes. In pregnancieswith exposure to taliglucerase alfa, four of six had
normal outcomes, one ended in spontaneous abortion and one in elec-
tive abortion.
In women who received imiglucerase, 56 of 62 pregnancies (90.3%;
outcome not speciﬁed for one) had normal outcomes and one ended
in elective abortion. Five events of spontaneous abortion were reported
in three patients, including onepatientwhohad three normal outcomes
before the loss and three after with exposure to imiglucerase.
3.5. Pregnancies in untreated patients
Most pregnancies in GOSwere not exposed to any GD-speciﬁc treat-
ment (336/453, 74.2%). For pregnancies with end dates available (n =
324), 135 occurred prior to 1991, before ERT was available. Of the 336
untreated pregnancies, 312 (92.9%) had normal outcomes (Table 4).
Twelve (3.6%) ended in spontaneous abortion, 11 (3.3%) in elective
abortion, and one in neonatal death (0.3%).
The patientwhose pregnancy resulted in neonatal death had normal
pregnancy outcomes approximately 2.5 years before the event and
1 year after the event, both without receiving GD-speciﬁc treatment.
She subsequently had a third normal outcome while receiving
velaglucerase alfa before conception and throughout pregnancy. One
patient experienced a spontaneous abortion when not receiving treat-
ment during pregnancy; approximately 2 years later she had a normal
pregnancy outcome while receiving velaglucerase alfa before concep-
tion and throughout pregnancy.
For pregnancies with end dates available, the percentage of spontane-
ous abortions in untreated pregnancies before 1991 (5/135, 3.7%) was
similar to that reported after 1991 (6/189, 3.2%). The percentage of normal
outcomes inuntreatedpregnancieswas 92.9% (95%CI, 89.6%–95.4%) com-
pared with 91.4% (95% CI, 84.7%–95.8%) in those exposed to GD-speciﬁc
treatment (p = 0.6830; Table 4). The percentage of spontaneous abor-
tions in untreated pregnancies was 3.6% (95% CI, 1.9%–6.2%), compared
with 6.9% (95% CI, 3.0%–13.1%) in those exposed to GD-speciﬁc treatment
(p = 0.1866). The median (IQR) age of patients at the end of treated
pregnancies was 31.9 (28.6, 35.0) years compared with 28.8 (24.2, 32.2)
years for untreated pregnancies (Supplementary Table 2).
3.6. Adverse events
An adverse event of gestational diabetes was reported for one
woman who received velaglucerase alfa during the second trimester
of a pregnancy with a normal outcome. Also reported was an event of
congenital abnormalities (polydactyly and possible micropenis) in a
baby with trisomy 13 born to a womanwhose pregnancy was recorded
as having a normal outcome. The woman had GBA1 genotype N370S/
L444P and received imiglucerase at 30 U/kg every other week for the
second half of her pregnancy. Both adverse events were deemed unre-
lated to treatment.
An adverse event of monoclonal gammopathy of undetermined sig-
niﬁcance (MGUS) was reported in a woman who had two untreatedttp://dx.doi.org/10.1016/j.bcmd.2016.10.003
Pregnancies reported
in GOS
n = 453 (189 patients)
Pregnancies in untreated
women with GD
n = 336 (143 patients) 
Pregnancies in women with GD
receiving GD-specific treatment 
n = 117 (68 patients) 
Pregnancies in women with GD
receiving other GD-specific
treatment (alglucerase,
imiglucerase, taliglucerase alfa)
n = 81 (41 patients) 
Pregnancies in women
with GD receiving
velaglucerase alfa
n = 36 (32 patients) 
Fig. 1. Pregnancy events in GOS. A total of 453 pregnancies with delivery or end dates from January 1959 to July 2015 have been reported in 189women whowere enrolled in GOS at the
time of the July 30, 2015 data extract. GD, Gaucher disease; GOS, Gaucher Outcome Survey.
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imately 5 years after her second pregnancy.
4. Discussion
We report fetal outcomes for 189GDpatients enrolled inGOS,which
includes outcomes from the largest cohort of velaglucerase alfa-treated
pregnant women published to date. Most pregnancies resulted inTable 3
GBA1 genotype, age, and treatment status during pregnancy in women with Gaucher disease i
Patient GBA1 genotype Age at pregnancy loss (years)
1 N370S/N370S 31.2
31.6
2 N370S/N370S 31.1
3 N370S/N370S 31.5
4 R496H/84GG 39.0
5 Missing 24.9
25.0
25.5
6 N370S/N370S 39.8
7 N370S/N370S 36.6
8 N370S/N370S 35.7
9 N370S/N370S 22.0
10 N370S/N370S 25.5
11 N370S/N370S 29.5
12 N370S/N370S 19.6
20.6
13 N370S/V433 L 23.3
14 N370S/P182T Missing
15 N370S/R496H 22.4
16 Missing 19.9
17 Missing 30.5
18 N370S/N370S 29.5
33.6
19 N370S/N370S 31.3
20 N370S/N370S 31.2
21 N370S/N370S 35.5
22 N370S/N370S 22.1
23 N370S/N370S 39.7
24 N370S/N370S 31.9
25 N370S/L444P 30.7
26 N370S/RecTL 24.3
26.3
27 Missing 23.4
28 N370S/N370S 28.9
EOW, every other week.
Gestational age at time of pregnancy loss and reasons for the loss were not collected in GOS.
In all but three patients (14, 20 and 23), those who experienced pregnancy losses had one or m
Please cite this article as: H. Lau, et al., Blood Cells Mol. Diseases (2016), hreported normal outcomes. Although the percentage of normal out-
comes in untreated pregnancies was similar to that in pregnancies ex-
posed to ERT, it is possible that untreated women may have had
milder GD than those who received ERT during pregnancy after it be-
came available in 1991 [2]. Women in the untreated pregnancy group
may also have been receiving treatment prior to pregnancy (then
discontinued treatment during pregnancy), thereby affording ameliora-
tion of disease burden before pregnancy [9]. Furthermore, more thann GOS who experienced pregnancy loss.
Type of pregnancy loss Treatment received during pregnancy
Spontaneous abortion Velaglucerase alfa 15 U/kg EOW
Spontaneous abortion Velaglucerase alfa 15 U/kg EOW
Spontaneous abortion Taliglucerase 15 U/kg EOW
Spontaneous abortion Imiglucerase 30 U/kg EOW
Spontaneous abortion Imiglucerase 15 U/kg EOW
Spontaneous abortion Imiglucerase (dose and frequency missing)
Spontaneous abortion Imiglucerase (dose and frequency missing)
Spontaneous abortion Imiglucerase (dose and frequency missing)
Elective abortion Imiglucerase 60 U/kg EOW
Elective abortion Taliglucerase alfa 60 U/kg EOW
Spontaneous abortion Untreated
Spontaneous abortion Untreated
Spontaneous abortion Untreated
Spontaneous abortion Untreated
Spontaneous abortion Untreated
Spontaneous abortion Untreated
Spontaneous abortion Untreated
Spontaneous abortion Untreated
Spontaneous abortion Untreated
Spontaneous abortion Untreated
Spontaneous abortion Untreated
Spontaneous abortion Untreated
Elective abortion Untreated
Elective abortion Untreated
Elective abortion Untreated
Elective abortion Untreated
Elective abortion Untreated
Elective abortion Untreated
Elective abortion Untreated
Elective abortion Untreated
Elective abortion Untreated
Elective abortion Untreated
Elective abortion Untreated
Neonatal death Untreated
ore normal pregnancy outcomes before and/or after their loss.
ttp://dx.doi.org/10.1016/j.bcmd.2016.10.003
Table 4
Pregnancy outcomes in women with Gaucher disease in GOS (453 pregnancies in 189 women).
Pregnancy outcome Untreated Treated (all) Velaglucerase alfa Other GD treatmenta
Pregnancies
n = 336
Patientsb
n = 143
Pregnancies
n = 117
Patientsb
n = 68
Pregnancies
n = 36
Patientsb
n = 32
Pregnancies
n = 81
Patientsb
n = 41
n (%) n n (%)c n n (%) n n (%)c n
Normal 312 (92.9%) 139 106 (91.4) 67 34 (94.4%) 32 72 (90.0%) 40
Spontaneous abortion 12 (3.6%) 11 8 (6.9%) 5 2 (5.6%) 1d 6 (7.5%) 4
Elective abortion 11 (3.3%) 10 2 (1.7%) 2 0 0 2 (2.5%) 2
Neonatal death 1 (0.3%) 1 0 0 0 0 0 0
Unknown 0 0 1 1 0 0 1 1
GD, Gaucher disease; GOS, Gaucher Outcome Survey.
a Other GD-speciﬁc treatments speciﬁed were alglucerase (n = 6), imiglucerase (n = 63), and taliglucerase alfa (n= 6); treatment type was unspeciﬁed in six pregnancies.
b More than one pregnancy could be reported for each patient.
c Percentages determined from total number of pregnancies with speciﬁed outcomes.
d Patient subsequently had a normal pregnancy outcome while receiving velaglucerase alfa before conception and during her ﬁrst and second trimesters.
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mutation allele, a genotype that is often associated with mild GD man-
ifestations [10].
Spontaneous abortion is a commonly reported outcome estimated
to occur in 12–24% of conﬁrmed pregnancies in the general population
[11]. The incidence of spontaneous abortion in GD patients in GOS
(4.4%) is not elevated compared with that of the general population al-
though estimates for the latter are based on much higher numbers of
pregnancies and more systematic methods of data collection than the
GOS analysis.
Two patients in GOS experienced spontaneous abortions when they
were untreated during pregnancy, and subsequently had normal preg-
nancy outcomes while receiving velaglucerase alfa during pregnancy.
The use of ERT during pregnancy in patients with GD has been associat-
ed previously with a reduced incidence of spontaneous abortions com-
pared with untreated pregnancies [2,6,12], though it is not possible to
draw this conclusion from our study based on the low number of spon-
taneous abortions reported.
Systematically collected data estimate that congenital abnormalities
are seen in 48.5 per 1000 live births for the general population in Israel
[13]. In GOS pregnancies, there was one report of a baby born with con-
genital abnormalities (polydactyly, possible micropenis, trisomy 13) to
a 31-year-old woman on imiglucerase. There were pregnancies report-
ed that ended in elective termination, but it is not known whether any
were due to detection of congenital abnormalities as the reasons for
the elective terminations were not provided. Most congenital abnor-
malities of known cause result from genetic aberrations, including chro-
mosomal abnormalities, single gene defects and multifactorial
inheritance (an interaction of genetic and environmental factors) [13].
An estimated 5–10% of all congenital abnormalities are caused by envi-
ronmental factors, which includes exposure to teratogenic drugs [13]. It
is not known whether recombinant β-glucocerebrosidase crosses the
placental barrier and thus whether it could cause congenital abnormal-
ities through a direct teratogenic effect (as opposed to miglustat, whichTable 5
Timing of exposure to velaglucerase alfa during pregnancy.
b1 month before
conception
First
trimester
Second
trimester
Third
trimester
Number of
patients
n = 32
Number of
pregnancies
n = 36
✓ ✓ ✓ ✓ 19 20
✓ ✓ ✓ 1 1
✓ ✓ ✓ 1 1
✓ ✓ ✓ 1 1
✓ ✓ 3 4
✓ 2 2
✓ 1 1
✓ 5 6
GOS, Gaucher Outcome Survey.
Please cite this article as: H. Lau, et al., Blood Cells Mol. Diseases (2016), hdoes cross the placenta) [14,15]. No adverse effects on embryo-fetal de-
velopment were seen in studies with velaglucerase alfa and
taliglucerase alfa in pregnant rats and rabbits; however, no well-
controlled reproduction studies have been conducted with ERT in
women [16–18].
While there is no evidence that ERT has a teratogenic effect on preg-
nancies in GD patients, its use can cause hypersensitivity or infusion-
related reactions that could potentially be associated with unfavorable
maternal or fetal outcomes during pregnancy. The ERTs for GD have
generally acceptable tolerability proﬁles, but hypersensitivity reactions,
including anaphylaxis, have been reported for imiglucerase, velaglucerase
alfa, and taliglucerase alfa [16–18].
Velaglucerase alfa has been shown to have an acceptable tolerability
proﬁle in clinical trials in which assessment of safety was a primary ob-
jective (in patients who were not pregnant) [4,19,20]. Of 54 patients
naïve to ERT who participated in velaglucerase alfa clinical trials, 28
(52%) experienced hypersensitivity reactions, the majority of which
were mild and occurred during the ﬁrst 6 months of treatment [17]. In
our analysis, there was only one adverse event of gestational diabetes
reported in awomanwho received velaglucerase alfa during the second
trimester of her pregnancy. The event was deemed unrelated to treat-
ment and her pregnancy had a normal outcome. No infusion-related re-
actions or drug-related adverse events attributed to velaglucerase alfa
were reported in this cohort of women during their pregnancies.
All 20 patients who received velaglucerase alfa prior to conception
and in all three trimesters of their pregnancies had normal pregnancy
outcomes. A further 14 of 16 pregnancies in patients who received
velaglucerase alfa at somepoint prior to conception and/or during preg-
nancy also had normal outcomes. For nearly half of dose entries report-
ed, velaglucerase alfa was received during pregnancy at b20 U/kg. This
result likely reﬂects the high proportion of pregnancies with exposure
to velaglucerase alfa reported from Israel (26/36, 72.2%), where ERT is
generally administered at lower doses compared with other countries
[21].
The analysis presented here is limited because GOS collects patient
data from real-world clinical settings and is not designed speciﬁcally
to investigate the effect of treatment on pregnancy outcome. The regis-
try also does not have strict inclusion and exclusion criteria such as
those in clinical trials, and may be subject to selection bias. Except for
live birth, congenital abnormality, and neonatal death, no data on neo-
natal outcomes are collected in GOS. No adverse neonatal outcomes re-
lated to treatment have been suggested in studies of pregnancies in
ERT-treated GD patients in which neonates were followed after birth
[12,22]. Furthermore, no information on the postpartumperiodwas col-
lected for GOS patients. This period is important to assess as patients
may experience GD-related complications following a pregnancy with
a normal outcome. Additional evidence is needed to better understand
how treatment during pregnancy inﬂuences complications and disease
course postpartum.ttp://dx.doi.org/10.1016/j.bcmd.2016.10.003
6 H. Lau et al. / Blood Cells, Molecules and Diseases xxx (2016) xxx–xxx5. Conclusions
Our results provide evidence thatmay aid GD treatment decisions so
that asymptomatic patients are not started on treatment unnecessarily
during pregnancy, and provide guidance for symptomatic patients
whomay become pregnant during treatment. The normal outcomes re-
ported for the 20 pregnancies exposed to velaglucerase alfa throughout,
adds to information in the literature suggesting that continuation of ERT
during pregnancy may be appropriate for GD patients.Authorship contributions
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